Diaceutics (DXRX) Trading Update summary

Financial performance and revenue growth

• Revenue increased 22% on a constant currency basis to £14.6 million in H1 2025, with a 3-year CAGR of 25%.

• Annual recurring revenue rose 16% to £16.4 million, now representing 70% of total H1 revenues.

• Positive adjusted EBITDA delivered in H1 2025, in line with board expectations.

• Order book for H2 2025 stands at £8.8 million, providing 79% visibility on FY 2025 analyst consensus estimates.

• Cash position at 30 June 2025 was £10.4 million, with no debt.

Commercial momentum and customer engagement

• Number of customer therapeutic brands grew 17% year-on-year.

• Eight enterprise-wide agreements secured, totaling £10.1 million in ARR across 35 therapeutic brands.

• Worked with 18 of the top 20 global pharma companies and 74 therapeutic brands across 43 customers in H1 2025.

• DXRX platform adoption continues to drive business momentum and customer engagement.

Strategic outlook and operational confidence

• Enhanced technologies and product offerings are supporting operational leverage and margin improvement.

• Commercial pipeline and platform expansion expected to drive further growth in H2 2025.

• Exploring market opportunities beyond precision medicine.

• Board reaffirms confidence in strategy, performance, and ability to meet FY 2025 growth and profitability targets.